Lead: In September, President Donald Trump and Health Secretary Robert F. Kennedy Jr. urged pregnant women to avoid Tylenol, citing a possible link to autism. A multidisciplinary team published a systematic review Friday in The Lancet Obstetrics, Gynaecology, & Women’s Health that reassessed the evidence through September and found no association between prenatal acetaminophen exposure and autism, ADHD or intellectual disability. The authors said the review was partly motivated by public confusion and a surge in patient concern after the White House statement. Their conclusion supports using acetaminophen as the preferred over‑the‑counter option for fever and pain in pregnancy when appropriate.
Key Takeaways
- The Lancet review screened thousands of papers and retained 43 studies that met strict inclusion criteria, relying on medical records or provider‑administered questionnaires rather than self‑report alone.
- Researchers used three analytical approaches—including sibling comparison studies—and all converged on no detectable link between acetaminophen in pregnancy and autism, ADHD, or intellectual disability.
- Two largest sibling‑comparison studies, considered most robust, found no association when controlling for shared genetics and household environment.
- Authors include Dr. Francesco D’Antonio (University of Chieti) and Dr. Asma Khalil (St. George’s Hospital, London); the study team is based in the U.K., Italy and Sweden.
- Some HHS officials criticized the review’s exclusions and interpretation, calling for continued study; authors and several outside experts praised the paper’s rigor.
- The review reinforces clinical guidance that acetaminophen remains the first‑line medication for managing fever and pain in pregnancy when medically indicated.
Background
Debate over acetaminophen (paracetamol) and neurodevelopmental outcomes in children intensified after a September White House news conference where President Trump and Health Secretary Robert F. Kennedy Jr. warned pregnant women to avoid Tylenol. That public warning came amid renewed calls by some researchers to probe prenatal medication exposures as possible factors in rising autism diagnoses.
Earlier observational studies and a 2023 review published in Environmental Health reported associations between maternal acetaminophen use and child neurodevelopmental outcomes, but many of those analyses relied on self‑reported medication use or did not fully account for confounding factors such as maternal health during pregnancy. Health authorities and clinicians were concerned that overly cautious public messaging could lead pregnant women to leave fevers untreated, which itself carries risks for mother and fetus.
Main Event
The new paper, published in The Lancet’s obstetrics and gynecology outlet, systematically searched the literature through September and applied three filters: excluding studies without comparative pregnancy groups, excluding research lacking medical records or provider‑verified medication data, and rating study quality to remove low‑reliability work. From thousands of candidate reports, 43 met the team’s prespecified standards.
After quality grading, the authors performed sensitivity analyses and then focused on two large sibling‑comparison cohorts. Those designs compare siblings discordant for in‑utero exposure—one sibling exposed to acetaminophen and another not—thereby controlling for shared genetics and family environment. In both sibling analyses, there was no evidence that prenatal acetaminophen raised the risk of autism, ADHD or intellectual disability.
Lead contributors framed the review as an effort to clarify public confusion following the White House announcement. Dr. Francesco D’Antonio said clinicians experienced an immediate surge in patient questions after the September remarks, with many women anxious about taking routine pain or fever medication during pregnancy.
Analysis & Implications
The study’s methods aim to reduce bias present in earlier work: by excluding studies that relied solely on maternal recall and by emphasizing medical record–based exposure assessment, the review reduces misclassification of both exposure and outcome. Sibling designs further mitigate confounding from unmeasured family‑level factors that can mimic a causal link in standard cohort studies.
Clinically, the finding supports continued guidance endorsing acetaminophen as the safest available over‑the‑counter analgesic and antipyretic for most pregnant patients. Untreated fever carries known risks in pregnancy, including maternal discomfort and potential fetal harms, so recommendations that sharply restrict acetaminophen without strong evidence could have unintended negative consequences.
Policy implications are mixed: the review is likely to reassure many clinicians and professional societies, but it may not settle public debate. Critics within HHS argued the paper excluded relevant studies and therefore risked bias; supporters counter that inclusion of low‑quality, self‑reported data can generate spurious associations. Future randomized or prospective studies with precise exposure measurement would strengthen causal inference, but may be difficult for ethical and logistical reasons.
Comparison & Data
| Study Type | Number of Studies Included | Main Finding |
|---|---|---|
| Medical‑record based cohorts | 43 (selected) | No association with autism, ADHD, intellectual disability |
| Sibling‑comparison analyses | 2 (largest cohorts) | No association after controlling shared family factors |
| Prior reviews including self‑report | Smaller totals | Reported associations but higher risk of confounding |
The table summarizes how the new review’s stricter inclusion criteria differ from earlier work that reported associations. By prioritizing provider‑verified exposure data and sibling comparisons, the Lancet review reduced several common sources of bias—particularly recall bias and unmeasured familial confounding—that can inflate associations in observational research.
Reactions & Quotes
Independent experts lauded the review’s rigor but noted it does not close every scientific question. Below are representative statements with context.
“I don’t think there’s a better way to analyze the data than this Lancet paper does.”
David Mandell, University of Pennsylvania (psychiatry professor)
Mandell praised the review’s comprehensive search and analytic choices, arguing that the three complementary methods (strict inclusion, quality grading, and sibling analyses) converged on the same null result and therefore strengthen confidence in the conclusion.
“It remains to be the first line treatment that we would recommend if the pregnant women have pain or fever.”
Dr. Asma Khalil, St. George’s Hospital (consultant obstetrician and fetal medicine specialist)
Khalil, a co‑author, emphasized clinical trade‑offs: fever and severe pain in pregnancy can pose risks, and clinicians should weigh those harms against unsubstantiated medication concerns when advising patients.
“According to HHS, many experts have expressed concern of the use of acetaminophen during pregnancy.”
Andrew Nixon, HHS spokesperson
HHS reiterated that some researchers remain worried about acetaminophen use and called for ongoing study; HHS also criticized the review’s exclusions, arguing the analysis may undercount evidence suggesting risk.
Unconfirmed
- Claim by some HHS officials that the review was engineered to produce a null result—this is an official critique but the review team and several independent experts dispute that characterization and provide methodological justification.
- Whether small, methodologically weaker studies showing associations reflect real effects in specific subgroups—this remains unresolved and would require targeted prospective research to confirm.
Bottom Line
The Lancet‑published systematic review synthesized higher‑quality observational evidence and sibling comparisons and found no link between prenatal acetaminophen and autism, ADHD or intellectual disability. The paper’s methods—restricting to medical‑record based exposure assessments, applying quality filters, and analyzing sibling cohorts—reduce several biases that likely affected earlier positive associations.
For clinicians and pregnant patients, the review supports current practice: acetaminophen remains the preferred over‑the‑counter choice for managing fever and pain when clinically indicated. Policymakers and researchers should continue to monitor evidence and prioritize well‑designed prospective studies, but communicators should avoid alarmist messages that could deter treatment of maternal fever and pain.
Sources
- NBC News — news report summarizing the Lancet review and public statements (news).
- The Lancet Obstetrics, Gynaecology, & Women’s Health — journal hosting the systematic review (academic journal/publisher).
- U.S. Department of Health and Human Services (HHS) — cited official statements and departmental commentary (official government source).
- Autism Science Foundation — expert commentary on autism research and public communication (nonprofit/advocacy).
- Environmental Health — earlier review by Dr. Andrea Baccarelli and colleagues reporting associations (academic journal).